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Abstract
Asthma is a chronic inflammatory disease affecting the lung, characterized by breathing difficulty during an attack following
exposure to an environmental trigger. Calcitonin gene-related peptide (CGRP) is a neuropeptide that may have a
pathological role in asthma. The CGRP receptor is comprised of two components, which include the G-protein coupled
receptor, calcitonin receptor-like receptor (CLR), and receptor activity-modifying protein 1 (RAMP1). RAMPs, including
RAMP1, mediate ligand specificity in addition to aiding in the localization of receptors to the cell surface. Since there has
been some controversy regarding the effect of CGRP on asthma, we sought to determine the effect of CGRP signaling
ablation in an animal model of asthma. Using gene-targeting techniques, we generated mice deficient for RAMP1 by
excising exon 3. After determining that these mice are viable and overtly normal, we sensitized the animals to ovalbumin
prior to assessing airway resistance and inflammation after methacholine challenge. We found that mice lacking RAMP1 had
reduced airway resistance and inflammation compared to wildtype animals. Additionally, we found that a 50% reduction of
CLR, the G-protein receptor component of the CGRP receptor, also ameliorated airway resistance and inflammation in this
model of allergic asthma. Interestingly, the loss of CLR from the smooth muscle cells did not alter the airway resistance,
indicating that CGRP does not act directly on the smooth muscle cells to drive airway hyperresponsiveness. Together, these
data indicate that signaling through RAMP1 and CLR plays a role in mediating asthma pathology. Since RAMP1 and CLR
interact to form a receptor for CGRP, our data indicate that aberrant CGRP signaling, perhaps on lung endothelial and
inflammatory cells, contributes to asthma pathophysiology. Finally, since RAMP-receptor interfaces are pharmacologically
tractable, it may be possible to develop compounds targeting the RAMP1/CLR interface to assist in the treatment of asthma.
Citation: Li M, Wetzel-Strong SE, Hua X, Tilley SL, Oswald E, et al. (2014) Deficiency of RAMP1 Attenuates Antigen-Induced Airway Hyperresponsiveness in
Mice. PLoS ONE 9(7): e102356. doi:10.1371/journal.pone.0102356
Editor: Oliver Eickelberg, Helmholtz Zentrum München/Ludwig-Maximilians-University Munich, Germany
Received April 29, 2014; Accepted June 18, 2014; Published July 10, 2014
Copyright:  2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by grants from National Institutes of Health/National Heart Lung and Blood Institute/National Institute of Diabetes and
Digestive and Kidney Diseases HD060860 and DK99156 to KMC, as well as 2U19A1077439-06 and P01 HL024136 to MFK. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: kathleen_Caron@med.unc.edu
. These authors contributed equally to this work.
Introduction
Asthma is a debilitating chronic disease affecting about 25
million people in the United States [1] that costs taxpayers over
$56 billion per year in medical costs and lost productivity [2].
Individuals prone to asthma have chronic inflammation of the
airways possibly caused by pre-sensitization of the immune system
to substances that are normally innocuous [3]. When these
immune cells become activated after recognition of a trigger,
smooth muscle contraction, edema, and mucus hypersecretion are
triggered, resulting in the appearance of symptoms. In addition to
environmental triggers, it is believed that genetic factors pre-
dispose individuals to asthma. To date, several GWAS studies
have identified SNPs that are correlated with asthma, including
loci harboring the IgE receptor [4,5], cytokines [4,6], and DNA
repair elements [4], highlighting the multifaceted nature of this
disease.
Prior to the discovery of the receptor activity-modifying proteins
(RAMPs), the exact receptors through which peptides such as
calcitonin gene-related peptide (CGRP) and adrenomedullin (AM)
acted remained unclear. Although it was believed that these
peptides signaled via G-protein coupled receptors (GPCRs), the
exact identity of these receptors was highly debated. With the
discovery of the RAMPs in 1998, it became clear that this was the
mechanism by which ligand specificity and receptor transportation
were dictated for some GPCRs [7]. Specifically, McLatchie et al
determined that CGRP interacted with the calcitonin receptor-like
receptor (Calcrl=gene; CLR=protein) in the presence of RAMP1,
while the association of RAMP2 with CLR produced an AM
receptor [7]. Since this initial study, it has been determined that
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the interaction between CLR and RAMP3 also produces an AM
receptor [8], although this does not appear to be the major AM
receptor since Ramp32/2 mice are viable [9], in contrast to the
embryonic lethality exhibited by Calcrl2/2 [10], Ramp22/2 [11]
and Adm2/2 [12] mice. The encoding of each RAMP by
individual genes located on separate chromosomes in humans
allows RAMP expression and thus, receptor function, to be finely
controlled in individual cell populations. Since the RAMPs confer
ligand specificity to GPCRs that may recognize multiple ligands,
this RAMP-receptor interface has great potential as a reliable
pharmaceutical target to allow for specific blockage or activation
of a single ligand without altering the signaling of other ligands
that utilize the same GPCR. In fact, compounds that block the
RAMP1/CLR interface are currently undergoing clinical trials for
the treatment of migraine pain mediated by CGRP signaling [13].
Calcitonin gene-related protein (CGRP) is a neuropeptide with
widespread expression throughout the central and peripheral
nervous systems [14]. This initial study by Rosenfeld et al
determined that the lung contains CGRP-positive nerve fibers
which tended to localize with the smooth muscle cells of the blood
vessels [14], indicating a possible role for CGRP in maintenance of
vascular tone. In fact, studies have demonstrated that CGRP is an
extremely potent vasodilator [15], which suggests that CGRP may
be protective in the context of asthma. However, reports
indicating that CGRP may promote inflammation through
enhancement of cytokine production [16] seem to suggest the
opposite effect of CGRP in the context of asthma. Studies
interrogating the role of CGRP during allergic asthma have been
conflicting [17,18], thereby necessitating further studies regarding
the role of the CGRP signaling pathway in allergic asthma. Since
CGRP signals via the Ramp1/Calcrl receptor interface, we chose to
examine the effect of Ramp1 loss on airway resistance and
inflammation in order to interrogate the CGRP signaling cascade
without altering the adrenomedullin signaling pathway. In this
study, we found that loss of Ramp1 attenuated the airway resistance
in mice sensitized and challenged with ovalbumin (OVA)
compared to similarly treated wildtype animals. These results
identify a role for Ramp1-mediated signaling in the hyperrespon-
siveness of the airways in this model of allergic asthma.
Methods
Generation of Mice with Targeted Deletion of the RAMP1
Gene
To generate the targeting vectors, a 129S6/SvEv genomic
library was screened for phage clones containing the 39 portion of
the Ramp1 gene using DNA fragments isolated from hRAMP1
expression plasmids (kindly provided by Dr. Steven Foord,
GlaxoSmithKline). Using convenient restriction sites within the
genomic clones, the 6.1 kb 59 region of homology was subcloned
into the multiple cloning site of the AMC1 gene-targeting vector
that contained a phosphoglycerate kinase-neomycin cassette
preceded by a LoxP site and a herpes simplex virus-thymidine
kinase cassette. A 1.2 kb PCR amplification fragment containing
exon 3 of the Ramp1 gene and a second LoxP site were inserted
between the 59 region of homology and the neomycin cassette and
a second 1.2 kb PCR amplification fragment from the 39 region of
homology was inserted after the neomycin cassette. The final
targeting vectors were linearized with Not I before electroporation
into TC1 embryonic stem cells from 129S6/SvEvTAC mice
following standard gene targeting methods. After applying positive
(G418) and negative (gancyclovir) selection, positive embryonic
stem cell clones were identified by Southern blot and/or PCR.
Then, a CMV-CRE plasmid was transfected into the positive
clones and the deletion of exon 3 and the neomycin cassette was
confirmed by Southern blot. The ES cells were injected into
C57BL6 blastocytes and male chimeric mice that transmitted the
targeted allele were bred to 129S6/SvEv females to establish
isogenic lines. For PCR-based genotyping of the Ramp1-targeted
locus the following primers were used: primer 1, 59-TCATGGG-
GACCTTTAGGTAAGC-39 and primer 2, 59 ACAG-
CAATCCTTCTACCTCAACAC-39. This PCR reaction gener-
ates a 1.6 kb band for the wildtype allele and a 0.4 kb band for the
Ramp1 knockout allele.
In addition to the Ramp12/2 mice generated for this study, the
previously described Calcrl+/2 [10], Calcrlfl/fl [11], and SM22-Cre
[19] lines were used for these studies. Unless otherwise noted,
experimental animals were 4–8 months old and maintained on an
isogenic 129S6/SvEv background. Control animals for all
experiments consisted of wild type age- and sex-matched
littermates. All experiments were approved by the Institutional
Animal Care and Use Committee of The University of North
Carolina-Chapel Hill and the Institutional Animal Care and Use
Committee of the University of California San Francisco.
Gene Expression Analysis
RNA was isolated from adult tissues using TRIzol reagent
(Invitrogen) in accordance with the manufacturer’s protocol. To
prevent genomic DNA contamination, RNA was treated with
DNaseI prior to cDNA synthesis with M-MLV reverse transcrip-
tase (Invitrogen, 28025-013). Ramp1 gene expression was assessed
by quantitative reverse transcription (qRT)-PCR using the
Mx3000P Real-Time PCR system from Stratagene. Primers for
Ramp1 amplification were 59-CCTCTGCTTACCTCTGA-
GATTG-39 and 59-ATCTGTGCAGTCTTCCTTGGAGT-39.
The probe sequence for Ramp1 detection was 59-FAM-ACACTT-
CATCACCACTGTGGGCATTCTG-TAMRA-39.
Blood pressure measurements and heart weight to body
weight measurement
Systolic, mean arterial pressure (MAP), and pulse pressure were
determined by the tail cuff method as described previously [20,21].
In order to determine the heart weight to body weight ratio, body
weights were recorded prior to euthanizing the animal. Then, the
entire heart was dissected from the chest and the great vessels and
any associated connective tissue were removed prior to measuring
the heart weight.
Induction of allergic inflammation and measurement of
airway resistance (RAW)
In order to sensitize mice to ovalbumin and generate a model of
asthma, an intraperitoneal injection consisting of 20 mg of chicken
ovalbumin (OVA, grade V, Sigma-Aldrich) emulsified in 200 ml of
aluminum hydroxide adjuvant (Alhydrogel, Accurate Chemical &
Scientific) was administered to each animal. Fourteen days later,
mice were challenged with either aerosolized saline (PBS) or 1%
ovalbumin (OVA) in 30-minute sessions for 5 consecutive days
using a whole-body exposure chamber. Twenty-four hours after
the last exposure, airway resistance (RAW) was measured in
anesthetized mice as previously described [22]. Basal RAW
measurements were made every 10 seconds for 1 minute prior
to serially challenging mice with aerosolized methacholine (MCh)
at the following concentrations: 10 mg/mL, 20 mg/mL, and
40 mg/mL. Mice were administered each concentration of MCh
for 20 second prior to recording the RAW at 10 second intervals
for 2 minutes immediately following each challenge period.
RAMP1 Knockout Mice
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Whole lung lavage in anesthetized mice
After RAW measurement, the chest was opened, and lungs were
promptly lavaged with PBS as described previously [23]. Lavage
fluid was kept on ice prior to centrifugation at 3606g for 10 min at
4uC. The supernatants were subsequently frozen at –80uC for
cytokine analysis.
Lung histopathology
Immediately following whole lung lavage, the lungs were
inflated with 10% neutral-buffered formalin at a constant pressure
of 20 cm using a syringe. Upon completion of lung inflation, the
trachea was tied off to prevent leakage of fixative. Then the lungs
were removed en bloc and immersed in 10% formalin for fixation.
Following fixation, the tissues were dehydrated with ethanol in
preparation for paraffin embedding. Using the left lobe of the
lungs, 5- to 6-mm serial sections were cut and stained with H&E to
assess general morphology.
Cytokine Measurements
The concentration of IL-4 in cell-free bronchoalveolar lavage
(BAL) fluid was measured using an ELISA kit (M4000B, R&D
Systems, Minneapolis, MN) according to the manufacturer’s
protocol.
Whole lung tissue digestion
Mice were euthanized with an intraperitoneal injection of 2.5%
Avertin, followed by removal of the lungs from the chest cavity.
The lungs were then placed in 5 ml of RPMI media containing
1.3 MandlU of Liberase and 0.2 mg DNase. The tissue was
dissociated using a lung-optimized program on a Miltenyi Biotec
gentleMACS machine followed by a 30-minute incubation at
37uC. Using the gentleMACS dissociator, the tissue was homog-
enized. Red blood cells were lysed, and 2 million cells were plated
for antibody staining.
Antibody staining for RAMP1 and CLR
Lung tissue homogenates were stained with the following
conjugated antibodies: anti-mouse CD45 AlexaFluor700 (1:300;
eBioscience), anti-mouse Siglec-F AlexaFluor647 (1:300; BD
Bioscience), anti-mouse Ly6g PeCy7 (1:400; BioLegend), anti-
mouse/human CD11b BV605 (1:2500; BioLegend), anti-mouse
CD11c BV510 (1:2000; BioLegend). A Zombie NIR fixable
viability kit (Biolegend) was used to differentiate live cells from
dead cells. To stain for CLR and RAMP1, rabbit anti-CLR (H42;
Santa Cruz) and rabbit anti-RAMP1 (FL-148; Santa Cruz)
primary antibodies were used, followed by a donkey anti-rabbit
AlexaFluor647 (1:200; Abcam) secondary. The samples were
analyzed by flow cytometry on a BD LSRFortessa.
Statistics
Statistical analyses were performed with student’s t-test. Error
bars represent standard error of the means. Differences were
considered significant with a p value of ,0.05.
Results
Generation of Ramp1 knockout mice
Previous studies have indicated an important role for CGRP in
the pathology of asthma [17,24]. Since CGRP can signal via the
Ramp1/Calcrl receptor, we were interested in determining whether
a loss Ramp1 could also result in an attenuation of airway
hyperresponsiveness after sensitization to ovalbumin and a
subsequent challenge period to reflect the findings of Aoki-Nagase
et al. Therefore, we developed a global Ramp1 knockout mouse
model, referred to as Ramp12/2 mice for the duration of this
article. Studies performed by other groups have demonstrated that
the second and third extracellular a–helices of Ramp1 contain
residues critical for CGRP binding and subsequent cAMP
generation [25]. Therefore, we decided to excise exon 3 of
isoform 1 of the mouse Ramp1 gene, which codes for these
extracellular loops, to remove these critical residues and prevent
the formation of a functional CGRP receptor. Although mouse
Ramp1 has three isoforms, including an isoform that utilizes an
alternate exon 3 from the form encoded by isoform 1, three-
dimensional structure prediction models of isoforms 2 and 3
indicate that these variants lack the third a–helix and have an
incomplete second a–helix. Additionally, isoforms 2 and 3 lack the
critical residues described by Simms et al as necessary for CGRP
interaction and cAMP generation [25], indicating that it is unlikely
that these isoforms can interact with CLR to form a functional
CGRP receptor. Using standard molecular biology techniques, we
flanked the third exon of the mouse Ramp1 gene with loxP sites to
generate the targeting vector (Figure 1A). We confirmed the
successful generation of this floxed allele by Southern blotting
(Figure 1B) prior to transfecting the positive ES cells with a
plasmid expressing Cre recombinase driven by the CMV
promoter in order to excise exon 3 in all cells, thereby generating
Ramp12/2 embryonic stem cells. We then, confirmed the
generation of the Ramp1 knockout allele by Southern blotting
(Figure 1C) before using these cells to generate the Ramp12/2
line. Finally, we used the primers shown in Figure 1A to perform
routine genotyping of the Ramp1+/2 offspring (Figure 1D).
Ramp12/2 mice are phenotypically normal
To ensure that Ramp12/2 animals do not have basal phenotypes
that might interfere with data interpretation, we began our studies
by performing a brief phenotypic analysis. We found that Ramp12/
2 animals breed normally, are viable, and have normal lifespans.
Our analysis of Ramp1 expression levels by qRT-PCR using brain
tissue revealed that Ramp12/2 animals do not have any detectable
levels of Ramp1 (Figure 2A), confirming the efficient knockdown
of Ramp1 with this targeting strategy. Tsujikawa et al used a
different targeting strategy to generate Ramp1 knockout animals
and found that Ramp12/2 mice were hypertensive [26]. Therefore,
we measured the mean arterial pressure, systolic pressure, and
pulse pressure in wildtype and Ramp12/2 animals by tail cuff
(Figure 2B). Our analysis revealed that Ramp12/2 animals have
blood pressures that are indistinguishable from wildtype controls.
We also assessed the heart weight to body weight (HW:BW) ratios
of wildtype and Ramp12/2 mice as a crude readout of potential
differences in hypertrophy. We found that the HW:BW ratios of
wildtype and Ramp12/2 mice were identical (Figure 2C),
supporting the conclusion that Ramp12/2 hearts are normal.
Finally, we found that compared to wildtype animals, Ramp12/2
mice express approximately 6 times more Calcrl in the lung
(WT=2106136 vs. Ramp12/213906459), indicating a potential
for enhanced AM signaling via RAMP2/CLR and RAMP3/CLR
complexes.
Loss of Ramp1 reduces airway resistance after ovalbumin
challenge
As previously stated, others have found that a loss of CGRP
resulted in an attenuation of airway resistance in a model of OVA-
induced asthma [17]. Since CGRP signals via the Ramp1/Calcrl
receptor interface, we hypothesized that a loss of Ramp1 would
lead to reduced airway resistance in the same model. Therefore,
we sensitized wildtype and Ramp12/2 animals as described in the
RAMP1 Knockout Mice
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methods section. These sensitized animals then inhaled either
aerosolized PBS or 1% OVA to stress the airways. When we
assessed the airway resistance (RAW) in response to MCh
inhalation, we found that Ramp12/2 animals challenged with an
inhalation of 1% OVA had maximum RAW measurements that
were significantly lower than wildtype animals challenged with 1%
OVA and similar to control animals that inhaled PBS (Figure 3A).
These data support the findings of Aoki-Nagase et al [17] that a
loss of CGRP signaling results in decreased airway resistance.
To further support our findings, we also tested whether a
reduction in the G-protein coupled receptor that associates with
Ramp1 to form the CGRP receptor, Calcrl, also attenuated the RAW
in this model. Since Calcrl2/2 animals are embryonic lethal during
mid-gestation [10], we used Calcrl+/2 mice, which express 50%
less Calcrl than wildtype littermates [10], to investigate the
importance of the receptor component in this phenomenon.
When we measured the RAW after sensitizing and challenging
wildtype and Calcrl+/2 mice as described previously, we found that
the Calcrl+/2 animals challenged with 1% OVA inhalation had
reduced RAW after inhaling 40 mg/mL of MCh compared to
similarly challenged wildtype animals (Figure 3B), indicating that
CGRP and both receptor components, Calcrl and Ramp1, are
important contributors to airway hyperresponsiveness in wildtype
animals.
One contributing factor to airway hyperresponsiveness is the
contraction of smooth muscle cells in the small airways. Therefore,
we were interested in determining whether CGRP acts on Calcrl
expressed by the smooth muscle cells to drive the hyperrespon-
siveness of the airways. To address this question, we crossed mice
with two floxed Calcrl alleles [11] to a smooth muscle-specific Cre
line, the SM22-Cre line [19], resulting in mice with a smooth
muscle-specific loss of Calcrl, and therefore, a loss of CGRP
signaling in this cell type. In contrast to our results with the global
Calcrl+/2 mice, SM22-Cre:Calcrlfl/f mice challenged with 1% OVA
experienced dramatically increased RAW with MCh challenge in a
manner similar to wildtype animals challenged with 1% OVA
(Figure 3C). These data indicate that CGRP is not acting directly
on the smooth muscle cells to drive airway constriction.
Loss of Ramp1 diminished lung inflammation
Since the OVA-induced model of allergic asthma results in the
infiltration of inflammatory cells and the production of many
cytokines, including IL-4 [27], we were interested in determining
whether the decreased RAW of the Ramp1
2/2 and Calcrl+/2mice
was associated with a reduction in inflammatory cells and
cytokines. We began by assessing the degree of inflammatory cell
infiltration by examining H&E stained lung sections (Figure 4).
While examining low power fields of wildtype (Figure 4A),
Ramp12/2 (Figure 4C), and Calcrl+/2 (Figure 4E) lungs, we
noticed patches of infiltrating cells present throughout the lobe of
the wildtype mice, while these patches were absent in Ramp12/2
and Calcrl+/2 mice. Upon closer examination (Figure 4B, D,
and F), it is clear that wildtype animals have patches of
inflammatory cells present in the airways, while these inflamma-
tory cells appear to be absent in the lungs of Ramp12/2 and
Calcrl+/2 animals. Finally, since IL-4 is a potent cytokine for TH2
cells, we assessed the levels of IL-4 in the BAL fluid. Using an
ELISA, we found that compared to PBS-challenged mice, IL-4
was increased by approximately 15-fold in wildtype mice
challenged with OVA (Figure 5). Interestingly, the concentration
of IL-4 in the BAL fluid of the OVA-challenged Ramp12/2 and
Calcrl+/2 mice was elevated only 3- to 4- fold compared to PBS-
challenged animals (Figure 5). Collectively, these data support the
conclusion that a loss of CGRP signaling via the Ramp1/Calcrl
interface results in a reduction of inflammation, thereby contrib-
uting to the reduced RAW after MCh challenge.
Immune cells in the lung express RAMP1 and CLR
We were interested in determining whether CLR and RAMP1
were expressed in endothelial or inflammatory cells given the fact
that the reduction or loss of these proteins reduced inflammation
and airway constriction and that this effect did not seem
dependent on the expression of CLR on smooth muscle cells.
Through a panel of antibody stains focused on immune cell
populations in the lung, we were able to study expression of
RAMP1 and CLR on inflammatory cells. Using the gating
strategy shown (Figure 6A), we were able to identify epithelial,
endothelial, and inflammatory cells. CD45- cells, which include
epithelium and endothelium, are positive for both CLR and
RAMP1 (Figure 6B). Interestingly, alveolar macrophages,
neutrophils, dendritic cells, and monocytes also expressed CLR,
and to a lesser extent, RAMP1 (Figure 6B). We also noted that
RAMP1 and CLR expression did not change following allergen
challenge with ovalbumin (Figure 6B). Together, these data
indicate that CLR and RAMP1 are expressed by endothelial, and
to some extent inflammatory cells, indicating that CGRP signaling
Figure 1. Targeting vector for the generation of Ramp1 knockout mice. A. Targeting vector design for excision of exon 3 from the mouse
Ramp1 gene. (E = EcoRI, B = BamHI) B. Southern blot to confirm generation of Ramp1 floxed allele. C. Southern blot confirming the successful
generation of Ramp1+/2 after Cre-mediated excision of exon 3. D. Routine genotyping using primers 1 (P1) and 2 (P2) shown in panel 1A.
doi:10.1371/journal.pone.0102356.g001
RAMP1 Knockout Mice
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in these cell populations may be responsible for driving the
observed airway hyperresponsiveness.
Discussion
In this study, we have demonstrated that the loss of RAMP1 in
sensitized animals results in a reduction of the airway resistance
compared to sensitized wildtype controls, indicating that RAMP1-
mediated signaling plays an important role in the hyperrespon-
siveness of the airways in this animal model of allergic asthma.
Additionally, we found evidence that the loss of RAMP1 and
reduced CLR attenuated lung inflammation. Importantly, endo-
thelial and immune cells of the lung express RAMP1 and CLR
before and after ovalbumin challenge. Together, these data
uncover a pathophysiologically relevant function for RAMP1
and CLR in airway resistance.
RAMP1 is known to interact with CLR to form a receptor for
CGRP, indicating that aberrant CGRP signaling may contribute
to the pathology of asthma. Indeed, several studies have
investigated the role of CGRP in the context of allergic asthma.
In one such study, Aoki-Nagase et al demonstrated that the loss of
a-CGRP in mice resulted in an amelioration of airway hyperre-
sponsiveness following airway sensitization [17]. Although Aoki-
Nagase et al did not find difference in inflammation [17] as we did,
this can perhaps be explained by the fact that RAMPs can interact
with other GPCRs [28], and therefore the RAMP1-mediated
effects on inflammation could be driven by a different receptor
Figure 2. Ramp1 knockout animals have normal cardiovascular
parameters. A. Knockdown of Ramp1 was confirmed by assessing the
relative expression level of Ramp1 in the brain by quantitative RT-PCR.
ND=not detected (n = 3 per group) B. Mean arterial pressure (MAP),
systolic pressure, and pulse pressure were measured by tail cuff. (n = 4
per group) C. Heart weight to body weight ratios (HW:BW) ratios were
assessed at 2–3 months of age. (n = 4–8) Data represent means6SEM.
***p,0.001.
doi:10.1371/journal.pone.0102356.g002
Figure 3. Attenuated airway resistance in sensitized Ramp12/2
and Calcrl+/2 animals compared to wildtype. A. Ramp1+/+ and
Ramp12/2 animals were sensitized to ovalbumin (OVA) as described in
the methods section prior to challenging the animals with either
aerosolized saline (PBS) or ovalbumin (OVA) for five days. The maximum
airway resistance (RAW max) at the basal state and after challenge with
aerosolized methacholine (MCh) was determined. (n = 3–4 per group) B.
Calcrl+/+ and Calcrl+/2- animals were sensitized to ovalbumin prior to
challenge as described in panel A. RAW max was determined for the basal
state and in response to MCh challenge 24 hours after challenge with
aerosolized PBS or OVA. (n = 3–4 per group) C. Calcrl was specifically
knocked down in smooth muscle cells using the SM22-Cre mouse.
These SM22-Cre:Calcrlfl/fl mice and wildtype controls were then
sensitized and challenged as described in panels 3A and 3B. (n = 4
per group) Data represent means6SEM.*p,0.05 Ramp12/2 (OVA)
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that has yet to be identified. Furthermore, Bonner et al provide
additional support for the theory that increased CGRP signaling
contributes to the pathology of allergic asthma in a study of
RAMP1 expression and localization in human asthma patients
[24]. Consistent with our results, this study revealed that human
airway epithelial cells express RAMP1 [24], and are therefore,
able to mediate responses to CGRP. Interestingly, the authors
found that in response to CGRP treatment, RAMP1 surface
expression was reduced due to receptor internalization [24].
Additionally, this study revealed that human asthma patients
displayed less RAMP1 on the surface of airway epithelial cells in
response to trigger peptide inhalation compared to non-asthmatic
controls [24], indicating that enhanced CGRP signaling via
RAMP1-mediated signaling contributes to asthma pathology.
Furthermore, Kay AB et al [29] found that human patients, who
responded to allergen exposure, in this case cat allergens, had
increased expression of CGRP. Interestingly, Kay AB et al found
that CGRP expression was primarily increased in T cells, as well
as the epithelium [29], further supporting the importance of these
cell populations in modulating the effect of CGRP in allergic
asthma. Finally, recent work performed by Bonner K et al [30] has
revealed that CCL17 can induce CGRP expression in lung
epithelial cells via CCR4, identifying one mechanism of CGRP
regulation. Together, these recent studies indicate that CGRP
signaling, presumably via inflammatory and lung epithelial cells,
plays an important role in the pathogenesis of allergic asthma,
further supporting our work presented here.
In our current study, we demonstrated that heterozygosity of
CLR resulted in reduced airway resistance following sensitization
and challenge. It is well known that, in addition to interacting with
RAMP1 to form a receptor for CGRP, CLR can interact with
RAMP2 and RAMP3 to form receptors for AM. Therefore, it is
possible that some of the reduced airway resistance observed in the
CLR heterozygotes is due to a reduction in AM signaling. Several
years ago, Yamamoto et al published a study investigating the
effect of AM heterozygosity on allergic asthma [31]. This study
revealed that a 50% reduction in AM signaling resulted in an
exacerbation of airway resistance [31], indicating that AM
signaling may be a protective peptide against asthma. One
possible explanation for the discrepancy between our data on CLR
heterozygotes and the data regarding AM heterozygotes by
Yamamoto et al is that the negative effects of CGRP signaling
on asthma might be more potent than the protective effects of AM,
and therefore diminished CGRP signaling may provide a greater
benefit to airway resistance than the corresponding reduction in
protective AM signaling. Additionally, it is possible that the
expression of RAMP2 and RAMP3 is less robust in the endothelial
cells of the lung compared to RAMP1; resulting in a preference of
CGRP signaling over AM signaling and therefore biasing the
phenotype towards that of the Ramp12/2 animals rather than
towards the phenotype of the Adm+/2 animals.
Pro- and anti-inflammatory signals play a critical role in
dictating whether and to what extent allergic inflammation will
occur. IL-4 is a potent pro-inflammatory cytokine that is
responsible for activating TH2 cells [32], inducing mucin gene
expression [33], enhancing the secretion of IgE [34], as well as up-
regulating IgE receptor expression [35]. Together, these effects
promote an immune response in the lungs and contribute to
airway hyperresponsiveness in asthma. In our study, we found that
Ramp12/2 animals had significantly less IL-4 present in the BAL,
indicating that the loss of RAMP1 signaling attenuates the
inflammatory response to inhaled triggers, which, in turn, prevents
airway hyperreponsiveness. Our finding that inflammatory cells
within the lung express RAMP1 and CLR, suggesting that direct
action of CGRP on inflammatory cells promotes an inflammatory
response within the lung, further supports this.
In summary, we have shown that a loss of RAMP1 signaling in
a model of allergic asthma results in improvements in both airway
Figure 4. Lung histology of wildtype, Ramp12/2, and Calcrl+/2
animals after sensitization and methacholine challenge. Wild-
type (A and B), Ramp12/2 (C and D)-, and Calcrl+/2 (E and F) mice were
sensitized with ovalbumin prior to a five day challenge period during
which mice inhaled aerosolized ovalbumin as described in the methods.
After measuring airway resistance in response to a methacholine
challenge, lungs were harvested for histological analysis. Low power
images obtained at 4x magnification are shown in panels A, C, and E,
while high power images taken at 40x magnification are shown in
panels B, D, and F.
doi:10.1371/journal.pone.0102356.g004
Figure 5. Reduced IL-4 levels from bronchoalveolar lavage
fluid of Ramp12/2 and Calcrl+/2 mice compared to wildtype. After
sensitizing wildtype, Ramp12/2, and Calcrl+/2 mice to ovalbumin and
challenging them with either saline (PBS) or ovalbumin as described in
the methods section, the airway resistance was determined prior to
collection of bronchoalveolar lavage (BAL) fluid. Using an ELISA assay,
the concentration of IL-4 in the BAL fluid was determined for each
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resistance and inflammation after challenge. Additionally, a
reduction of CLR in the lung also reduced the airway resistance,
indicating that the CLR/RAMP1 complex, which is the receptor
for CGRP, is a major mediator of pathological signals in allergic
asthma. Finally, we report that endothelial as well as inflammatory
cells within the lung express both RAMP1 and CLR, indicating
that action of CGRP on these cell populations may contribute to
the observed pathology in this model of allergic asthma. Since
drug compounds can be developed to specifically target RAMP-
receptor interfaces, compounds targeting the CLR/RAMP1
interface may be useful in providing relief from asthma.
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